MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Oncomed Pharmaceuticals Company Profile (NASDAQ:OMED)

Consensus Ratings for Oncomed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.50 (90.04% upside)

Analysts' Ratings History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetActions
6/2/2015Piper JaffraySet Price TargetBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2015BMO Capital MarketsSet Price TargetBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2014BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014JMP SecuritiesInitiated CoverageOutperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Jefferies GroupInitiated CoverageMarket Outperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2014BMO Capital MarketsReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2014MizuhoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2014Jefferies GroupLower Price Target$50.00 -> $48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2014MizuhoInitiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/17/2014Piper JaffrayBoost Price Target$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2013Jefferies GroupBoost Price TargetBuy$27.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/4/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha